Global Soliris Drug Market Size By Type (Plasma Exchange, Plasma Infusion), By Application (PNH, aHUS), By Region, And Segment Forecasts, 2023 to 2032

The Global Soliris Drug Market was valued at USD 4.6 billion in 2023 and is projected to reach USD 7.9 billion by 2031, growing at a CAGR of 6.9% during the forecast period (2023–2031). Soliris (eculizumab), developed by Alexion Pharmaceuticals (now part of AstraZeneca), is a monoclonal antibody that inhibits the complement protein C5, providing therapeutic benefits for rare, life-threatening disorders such as paroxysmal nocturnal hemoglobinuria (PNH), atypical hemolytic uremic syndrome (aHUS), and generalized myasthenia gravis (gMG). The growing incidence of rare diseases, coupled with increased diagnosis rates and treatment approvals across new indications, is driving significant market demand globally.

Drivers:

1. Rise in Rare Disease Diagnoses:

As diagnostic capabilities improve and awareness increases globally, more patients with rare diseases such as PNH and aHUS are being identified and treated with targeted therapies like Soliris.

2. Regulatory Approvals for Expanded Indications:

Soliris continues to gain regulatory approvals for new indications across different countries, expanding its patient base and enhancing commercial success.

3. Premium Pricing & Reimbursement Policies:

Despite its high cost, Soliris benefits from favorable reimbursement policies across developed markets due to its designation as an orphan drug for life-threatening conditions.

Restraints:

1. High Treatment Costs:

Soliris is among the most expensive drugs globally, with annual treatment costs exceeding USD 500,000 per patient. This limits its adoption in developing markets and strains healthcare budgets.

2. Biosimilar Threats and Market Exclusivity Expiry:

With patent expirations on the horizon, biosimilars and competitive complement inhibitors pose a potential threat to Soliris' market share in coming years.

Opportunity:

1. Emerging Market Penetration:

Improved healthcare infrastructure and access to orphan drugs in emerging markets such as Latin America and Asia-Pacific offer growth avenues for Soliris.

2. Pipeline Progression & Combination Therapies:

Ongoing research into combination therapies and newer formulations like subcutaneous versions may further boost patient compliance and expand Soliris’ clinical footprint.

Market by System Type Insights:

Soliris is administered primarily as an Intravenous (IV) Infusion, which continues to dominate the market. However, future demand may shift toward Subcutaneous Delivery Systems, currently under clinical trials, due to patient convenience and potential cost-efficiency.

Market by End-Use Insights:

The Hospital Pharmacies segment held the largest share in 2023 due to the specialized nature of Soliris administration and patient monitoring requirements. Specialty Clinics are expected to see increasing uptake due to decentralization trends and specialized rare disease management.

Market by Regional Insights:

North America held the largest market share in 2023, supported by advanced healthcare systems, broad insurance coverage, and early access to innovative therapies. Europe followed, driven by centralized rare disease registries and strong regulatory frameworks. Asia-Pacific is anticipated to register the fastest growth during the forecast period, owing to increasing rare disease awareness and improving healthcare investments.

Competitive Scenario:

The global Soliris Drug Market is dominated by AstraZeneca (Alexion Pharmaceuticals). However, competitors are emerging as biosimilar development advances and other complement inhibitors (like Ultomiris and Crovalimab) enter the market. Strategic initiatives include:

2023: AstraZeneca launched Soliris in new emerging markets with full reimbursement coverage for approved indications.

2024: Ongoing Phase III trials for subcutaneous formulations to enhance patient convenience and adherence.

2025: Competitor Roche progressed its C5 inhibitor Crovalimab through regulatory pathways in Europe and Asia.

Scope of Work – Global Soliris Drug Market

Key Market Developments:

2023: AstraZeneca expanded Soliris access in Latin America through public-private partnerships.

2024: FDA granted Orphan Drug Designation to Soliris for an additional autoimmune neurological indication.

2025: Biosimilar developers initiated Phase I trials for C5 inhibitors, signaling increased competitive pressure.

FAQs:

What is the current market size of the Global Soliris Drug Market?

The market was valued at USD 4.6 billion in 2023.

What is the major growth driver of the Global Soliris Drug Market?

Increasing diagnosis of rare diseases and expanding treatment indications.

Which is the largest region during the forecast period in the Global Soliris Drug Market?

North America leads due to advanced healthcare infrastructure and favorable reimbursement.

Which segment accounted for the largest market share in the Global Soliris Drug Market?

Hospital pharmacies dominated the market in 2023 due to the drug’s administration requirements.

Who are the key market players in the Global Soliris Drug Market?

Key players include AstraZeneca (Alexion), Roche, and potential biosimilar developers entering post-2025.